Min Wu

发表

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Xiaojiao Li, Hong Zhang, Yue Hu, 2021, Expert opinion on investigational drugs.

Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects

Hong Zhang, Yanhua Ding, Z. Jiao, 2019, Clinical pharmacology in drug development.

S-amlodipine–bisoprolol combination therapy caused elevated transaminases and triglyceride levels in healthy Chinese subjects: a randomized controlled, open-label, multiple-dose pharmacokinetic interaction study

J. Niu, Xiaojiao Li, Hong Zhang, 2019, Expert opinion on drug metabolism & toxicology.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

J. Niu, Xiaojiao Li, Hong Zhang, 2018, The Journal of pharmacy and pharmacology.

Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial

J. Niu, Hong Zhang, Yanhua Ding, 2021, Antimicrobial agents and chemotherapy.

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes

Z. Ning, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus

Xiaojiao Li, Hong Zhang, Yan-hua Ding, 2021, Clinical pharmacology in drug development.

Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects

Hong Zhang, Yanhua Ding, Xiping Liu, 2021, Expert opinion on investigational drugs.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects

Qi Zhang, Xiaojiao Li, Hong Zhang, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2018, Front. Pharmacol..

Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Expert opinion on investigational drugs.

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Yanhua Ding, Hong Wang, Cuiyun Li, 2021, Expert opinion on investigational drugs.

Comparison of the Pharmacokinetics of Generic Versus Branded Obeticholic Acid in a Chinese Population: Effects of Food and Sex

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Clinical pharmacology in drug development.

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Shiping Ma, Chengluan Xuan, Xiaojiao Li, 2022, Annals of medicine.

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

X. Yang, Xiaojiao Li, Hong Zhang, 2021, Frontiers in Pharmacology.

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers

Xiaojiao Li, Yanhua Ding, Min Wu, 2021, Cancer Chemotherapy and Pharmacology.

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2018, Front. Pharmacol..

A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers

Xiaojiao Li, Yanhua Ding, Min Wu, 2021, Expert opinion on drug metabolism & toxicology.

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

Hong Zhang, Yanhua Ding, Min Fang, 2022, Frontiers in Pharmacology.

Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, CNS Drugs.

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Pharmacology research & perspectives.

Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals

J. Niu, Xiaojiao Li, Hong Zhang, 2021, Expert opinion on investigational drugs.

The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability

Ting Xu, Xiaojiao Li, Hong Zhang, 2022, Expert opinion on investigational drugs.

Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects

J. Niu, Xiaojiao Li, Hong Zhang, 2017, Hepatology International.

Randomised clinical trial: safety, efficacy and pharmacokinetics of HS‐10234 versus tenofovir for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Alimentary Pharmacology and Therapeutics.

Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

X. Yang, Xiaojiao Li, Hong Zhang, 2022, BioDrugs.

A Reference‐Scaled Average Bioequivalence Study of Azithromycin Tablets Manufactured in China and the United States: An Open‐Label, Randomized, Single‐Dose, 3‐Way Crossover Study in Healthy Chinese Subjects Under Fasted and Fed Conditions

Yanhua Ding, Cuiyun Li, Min Wu, 2022, Clinical pharmacology in drug development.

Tolerability, pharmacokinetics and antiviral activity of rHSA/IFN&agr;2a for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2017, British journal of clinical pharmacology.

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Frontiers in Pharmacology.

Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2019, Antiviral research.

Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects

Hong Zhang, Yanhua Ding, Cuiyun Li, 2021, Expert opinion on drug metabolism & toxicology.

Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations.

Y. Qiao, J. Niu, Hong Zhang, 2017, Chemical & pharmaceutical bulletin.

Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-Deficiency Anemia.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Annals of medicine.

A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men

Xiaojiao Li, Hong Zhang, Haijing Wei, 2021, Expert Opinion on Biological Therapy.

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

QUAN LIU, J. Niu, Xiaojiao Li, 2020, Frontiers in Pharmacology.

Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Antiviral research.

Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Expert Opinion on Investigational Drugs.

FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB

He Gao, Yanhua Ding, A. Luk, 2019, Poster Presentations.

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Huanming Chen, Hui Lu, J. Niu, 2023, BMC Medicine.

Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects

Qi Zhang, Xiaojiao Li, Hong Zhang, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4‐Way Replicate Crossover Investigation by a Reference‐Scaled Average Bioequivalence Approach

Bin Liu, Yanhua Ding, Y. Ding, 2018, Clinical pharmacology in drug development.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Frontiers in Pharmacology.

Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Expert opinion on investigational drugs.

Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects

Yingjie Guo, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

A Randomized Dose-Escalation Study on the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of a Novel Recombinant Human Albumin in Healthy Subjects.

Jia-jun Cheng, Hong Zhang, Yanhua Ding, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.